The European LeukemiaNet
220 Participating Centers in 44 Countries with more than 1000 researchers and clinicians are cooperating in the European LeukemiaNet. The objective is to integrate the about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a network promoting cooperative research for curing leukemia.
19. ELN/22. KNL Symposium
Program
The 19. ELN/22. KNL Symposium will take place at the Congress Center Rosengarten, Mannheim on April 18, 2023, 8:00 - 20:00, followed by a working dinner in the foyer. The Symposium will have 15 sessions including 13 research sessions on the various types of leukemia and interdisciplinary specialities, 1 plenary session for summary reports and 1 plenary session reserved for up to 6 keynote lectures. A draft version of the evolving program is attached. For invitation, please, contact eva.lehrke@text-event.de
Download
Photos of the 19. ELN/22. KNL Symposium on April 18, 2023 (Group Photo, Keynote Lectures, Merit Awards) can be accessed here:
https://schaefer-werbeagentur.de/photographie/eln-symposium-2023/
ELN Breakfast Meeting
The next ELN Breakfast Meeting is planned in San Diego at ASH on Sunday, 10.12.2023, 6-10 AM as usual
Network info and goals
220 Participating Centers in 44 Countries with more than 1000 researchers and clinicians are cooperating in the European LeukemiaNet. The objective is to integrate the about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a network promoting cooperative research for curing leukemia.
Achievements of the ELN
Achievements in addition to the integration of leukemia research among its more than 1000 physicians and researchers and 220 institutions are the more than 100 management recommendations and guidelines for all forms of leukemia and related interdisciplinary specialities. A selection of the recommendations 2016-2018 is included in the attachment. We also list a selection of publications by others which carry the European LeukemiaNet in their titles. The key instrument of integration are regular meetings, in particular the annual ELN symposium at no cost for participants
Definition and funding of the European LeukemiaNet
The European LeukemiaNet is a publicly funded research network of excellence. Goal is cure of leukemia by integration of European leukemia research and spread of excellence. The website delivers information for physicians, researchers and the public on the disease, ongoing clinical trials, research projects and organizational matters. You can get information about the European LeukemiaNet in various European languages. The European LeukemiaNet was funded by the 6th Framework Program of the European Community until 2011, by the European Research Foundation until 2015 and is currently funded by the ELN-Foundation.
ELN Steering Committee (ELN SC)
ELN SC members
- Jane Apperley
- Tiziano Barbui
- Gianni Barosi
- Marie C. Bené
- Lars Bullinger
- Felipe Casado
- Sabina Chiaretti
- Jacqueline Cloos
- Carlo Croce
- Michael Deininger
- Hartmut Döhner
- Hervé Dombret
- Martin Dugas
- Hermann Einsele
- Pierre Fenaux
- Robin Foa
- Arnold Ganser
- Paolo Ghia
- Nicola Gökbuget
- Francois Guilhot
- Detlef Haase
- Claudia Haferlach
- Torsten Haferlach
- Jesus Hernandez
- Michael Heuser
- Andreas Hochhaus
- Dieter Hoelzer
- Jean-Jacques Kiladjian
- Hans-Jochem Kolb
- Per Ljungman
- Francois-Xavier Mahon
- Carsten Müller-Tidow
- Dietger Niederwieser
- Gert Ossenkoppele
- Elena Parovichnikova
- Markus Pfirrmann
- Josep Ribera
- Harald Rieder
- Gianantionio Rosti
- Giuseppe Saglio
- Miguel Sanz
- Susanne Saußele
- Hubert Serve
- Leif Stenke
- Christian Thiede
- Theo de Witte
- Gina Zini
- Rüdiger Hehlmann